BCDA
Price
$2.25
Change
+$0.11 (+5.14%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
10.41M
MDGL
Price
$334.60
Change
+$10.62 (+3.28%)
Updated
Apr 2 closing price
Capitalization
7.39B
40 days until earnings call
Ad is loading...

BCDA vs MDGL

Header iconBCDA vs MDGL Comparison
Open Charts BCDA vs MDGLBanner chart's image
BioCardia
Price$2.25
Change+$0.11 (+5.14%)
Volume$389
Capitalization10.41M
Madrigal Pharmaceuticals
Price$334.60
Change+$10.62 (+3.28%)
Volume$365.42K
Capitalization7.39B
BCDA vs MDGL Comparison Chart
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCDA vs. MDGL commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a StrongBuy and MDGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (BCDA: $2.14 vs. MDGL: $334.60)
Brand notoriety: BCDA and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 284% vs. MDGL: 71%
Market capitalization -- BCDA: $10.41M vs. MDGL: $7.39B
BCDA [@Biotechnology] is valued at $10.41M. MDGL’s [@Biotechnology] market capitalization is $7.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 3 bullish TA indicator(s).

  • BCDA’s TA Score: 4 bullish, 5 bearish.
  • MDGL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BCDA is a better buy in the short-term than MDGL.

Price Growth

BCDA (@Biotechnology) experienced а -18.63% price change this week, while MDGL (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

BCDA is expected to report earnings on Aug 13, 2024.

MDGL is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.39B) has a higher market cap than BCDA($10.4M). MDGL YTD gains are higher at: 8.436 vs. BCDA (-1.835). BCDA has higher annual earnings (EBITDA): -7.69M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. BCDA (4.93M). BCDA has less debt than MDGL: BCDA (1.05M) vs MDGL (120M). MDGL has higher revenues than BCDA: MDGL (180M) vs BCDA (71K).
BCDAMDGLBCDA / MDGL
Capitalization10.4M7.39B0%
EBITDA-7.69M-450.12M2%
Gain YTD-1.8358.436-22%
P/E RatioN/AN/A-
Revenue71K180M0%
Total Cash4.93M926M1%
Total Debt1.05M120M1%
FUNDAMENTALS RATINGS
BCDA vs MDGL: Fundamental Ratings
BCDA
MDGL
OUTLOOK RATING
1..100
474
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
10028
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4541
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (69) in the Pharmaceuticals Other industry is in the same range as BCDA (75) in the null industry. This means that MDGL’s stock grew similarly to BCDA’s over the last 12 months.

MDGL's Profit vs Risk Rating (28) in the Pharmaceuticals Other industry is significantly better than the same rating for BCDA (100) in the null industry. This means that MDGL’s stock grew significantly faster than BCDA’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as BCDA (100) in the null industry. This means that MDGL’s stock grew similarly to BCDA’s over the last 12 months.

MDGL's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as BCDA (45) in the null industry. This means that MDGL’s stock grew similarly to BCDA’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as BCDA (100) in the null industry. This means that MDGL’s stock grew similarly to BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDAMDGL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 7 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Ad is loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSLV11.600.08
+0.69%
Sprott Physical Silver Trust
BRF12.990.04
+0.33%
VanEck Brazil Small-Cap ETF
IGTR24.480.05
+0.20%
Innovator Gradient Tactical Rot Str ETF
NCZ11.770.02
+0.17%
Virtus Convertible & Income Fund II
PCN13.64N/A
N/A
PIMCO Corporate & Income Strategy Fund

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been closely correlated with SMMT. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCDA jumps, then SMMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
-15.75%
SMMT - BCDA
68%
Closely correlated
-2.54%
XRTX - BCDA
43%
Loosely correlated
-5.94%
MDGL - BCDA
29%
Poorly correlated
-2.19%
INO - BCDA
28%
Poorly correlated
-7.98%
KOD - BCDA
28%
Poorly correlated
-8.73%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+3.28%
KANT - MDGL
62%
Loosely correlated
+7.22%
ALXO - MDGL
56%
Loosely correlated
-2.70%
ZNTL - MDGL
51%
Loosely correlated
-2.52%
CGEM - MDGL
50%
Loosely correlated
+4.27%
TSVT - MDGL
50%
Loosely correlated
+0.20%
More